PRLX-93936 – 1 mg

Brand:
Cayman
CAS:
903499-49-0
Storage:
-20
UN-No:
Non-Hazardous - /

PRLX-93936 is an analog of erastin (Item No. 17754) that has antitumor activity.{37735} It inhibits the hypoxia-inducible factor 1 (HIF-1) signaling pathway under hypoxic conditions (IC50 = 0.09 μM in a cell-based reporter assay).{37736} PRLX-93936 (1 μM) also inhibits hypoxia-induced increases in HIF-1α expression in ME-180 cervical cancer cells. It inhibits the growth of HT-1080 fibrosarcoma, OVCAR-5 ovarian cancer, BJELR tumorigenic primary fibroblast, and PANC-1 pancreatic cancer cells with IC50 values of less than 100 nM.{37735} PRLX-93936 inhibits tumor growth in PANC-1 and HT-1080 xenograft models when administered at a dose of 50 mg/kg and induces tumor regression when administered at a dose of 100 mg/kg.  

 

Available on backorder

SKU: 25631 - 1 mg Category:

Description

An erastin analog that has antitumor activity; inhibits the HIF-1 signaling pathway under hypoxic conditions (IC50 = 0.09 μM in a cell-based reporter assay); inhibits hypoxia-induced increases in HIF-1α expression in ME-180 cervical cancer cells at 1 μM; inhibits the growth of HT-1080 fibrosarcoma, OVCAR-5 ovarian cancer, BJELR tumorigenic primary fibroblast, and PANC-1 pancreatic cancer cells (IC50s = <100 nM); inhibits tumor growth in PANC-1 and HT-1080 xenograft models at 50 mg/kg and induces tumor regression at 100 mg/kg


Formal name: 3-(2-ethoxyphenyl)-2-(1-piperazinylmethyl)-4(3H)-quinazolinone

Synonyms: 

Molecular weight: 364.4

CAS: 903499-49-0

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals||Research Area|Cancer|Transcription Factors|HIF-1α||Research Area|Cancer|Tumor Microenvironment